Jatenzo and Bupropion Interaction: Safety, Risks, and Monitoring

Why This Combination Comes Up in Clinical Practice

Men with hypogonadism frequently present with comorbid depression. The overlap is not coincidental. A cross-sectional analysis of 3,987 men in the European Male Ageing Study found that total testosterone below 8 nmol/L was associated with a 2.5-fold increased odds of depressive symptoms after adjustment for age, BMI, and chronic illness 1. Bupropion, an aminoketone-class norepinephrine-dopamine reuptake inhibitor (NDRI), is a common antidepressant choice in this population partly because it carries a lower risk of sexual side effects compared to SSRIs 2.

Jatenzo received FDA approval in March 2019 as the first oral testosterone undecanoate for male hypogonadism 3. Its unique lymphatic absorption pathway distinguishes it from older oral androgens like methyltestosterone, which carried hepatotoxicity risks. Because both drugs are prescribed long-term, prescribers need clarity on the interaction profile.

The CYP2D6 Pathway: How Bupropion Affects Testosterone Metabolism

Testosterone is metabolized through several enzymatic pathways. The primary routes involve CYP3A4 and CYP3A5 in the liver, converting testosterone to 6β-hydroxytestosterone and other metabolites. CYP2D6 contributes a minor fraction. This is worth stating plainly.

Bupropion is a potent CYP2D6 inhibitor. The FDA label for Wellbutrin XL states that co-administration of bupropion with desipramine (a CYP2D6 substrate) increased desipramine's AUC by approximately 5-fold 4. That degree of inhibition is significant for drugs primarily cleared through CYP2D6. Testosterone, however, is not one of those drugs.

Because CYP2D6 represents a minor metabolic route for testosterone, inhibition by bupropion is unlikely to produce clinically meaningful changes in serum testosterone concentrations. The Jatenzo prescribing information does not list bupropion as a contraindicated or dose-limiting co-medication 3. No published pharmacokinetic studies have directly measured the magnitude of this interaction in vivo.

A practical comparison: CYP3A4 inhibitors like ketoconazole have a far greater impact on testosterone clearance. The Endocrine Society's 2018 clinical practice guideline on testosterone therapy notes that strong CYP3A4 inhibitors warrant dose monitoring 5. Bupropion does not fall into that category.

Seizure Threshold: The More Clinically Relevant Concern

Bupropion carries a well-documented, dose-dependent seizure risk. The FDA label reports an incidence of approximately 0.4% (4 per 1,000) at doses up to 450 mg/day, rising sharply at higher doses 4. This risk led to a temporary market withdrawal in 1986 and subsequent dose-ceiling restrictions.

Testosterone's relationship to seizure threshold is less straightforward. Animal data suggest that supraphysiologic androgen levels can lower seizure threshold in rodent models, while physiologic replacement may have a neutral or mildly protective effect 6. In human clinical practice, seizure is not listed as an adverse event in Jatenzo's key trial data. The Jatenzo phase 3 trial (SOAR, N=166) reported no seizure events across 12 months of treatment 7.

The practical risk framework is this: if a patient has pre-existing seizure risk factors (history of seizures, eating disorders, alcohol withdrawal, CNS tumors, concurrent medications that lower seizure threshold), adding both bupropion and testosterone requires a documented risk-benefit discussion. For patients without these risk factors, the combination does not appear to carry additive seizure risk based on available evidence. No case reports in PubMed document seizures specifically attributed to the bupropion-testosterone combination.

Blood Pressure: An Overlapping Adverse Effect

Both medications can raise blood pressure independently, and this shared effect deserves more clinical attention than the CYP2D6 interaction.

Jatenzo's FDA label includes a boxed warning about blood pressure increases. In the SOAR trial, systolic BP increased by a mean of 3-5 mmHg, and 7.2% of patients developed new-onset hypertension 3. The Jatenzo REMS program originally required prescriber certification to manage this risk, though the REMS was later modified. Bupropion's label reports hypertension in approximately 2% of patients at therapeutic doses 4.

When the two drugs are co-prescribed, blood pressure monitoring becomes more important than usual. The American Heart Association defines stage 1 hypertension as 130-139/80-89 mmHg 8. A patient entering treatment at 128/78 could tip into the hypertensive range with relatively modest additive effects from both drugs.

Recommended approach: obtain baseline BP before starting either agent. Recheck at 2, 4, and 6 weeks after adding the second drug. If systolic rises above 140 mmHg or diastolic above 90 mmHg, consider dose reduction or antihypertensive therapy before discontinuing either medication.

Polycythemia Risk: Testosterone's Hematologic Effect and Bupropion's Neutrality

Erythrocytosis (hematocrit above 54%) is the most common dose-limiting adverse effect of testosterone therapy. The Endocrine Society guideline recommends checking hematocrit at baseline, 3-6 months after initiation, and then annually 5. In the Testosterone Trials (TTrials, N=790 men aged 65+), testosterone gel increased hematocrit by a mean of 2.6 percentage points over 12 months 9.

Bupropion does not affect erythropoiesis. It does not augment or mitigate testosterone's hematologic effects. This makes it a pharmacologically neutral co-medication from a polycythemia standpoint, unlike certain drugs (e.g., erythropoietin-stimulating agents) that would compound the risk.

If hematocrit exceeds 54% during combination therapy, the intervention targets testosterone: dose reduction, switch to a lower-absorption formulation, or therapeutic phlebotomy. Bupropion does not need to be adjusted for this reason.

Hepatic Considerations Specific to Jatenzo

Older oral androgens (methyltestosterone, fluoxymesterone) were 17α-alkylated and carried significant hepatotoxicity risk, including peliosis hepatis and cholestatic jaundice. Jatenzo is not 17α-alkylated. Its absorption occurs primarily via the intestinal lymphatic system, bypassing first-pass hepatic metabolism to a significant degree 10.

Bupropion is extensively metabolized by the liver, primarily through CYP2B6. In patients with hepatic impairment (Child-Pugh class B or C), bupropion AUC increases substantially, and the FDA label recommends dose reduction 4.

For patients with mild hepatic impairment, the combination is generally manageable with standard monitoring (liver function tests at baseline and periodically). For patients with moderate-to-severe hepatic impairment, bupropion dosing must be reduced per labeling, and Jatenzo's prescribing information advises caution in this population due to limited data.

Mood and Psychiatric Monitoring

Dr. Adrian Dobs, an endocrinologist at Johns Hopkins who participated in early testosterone undecanoate clinical research, has noted: "When we treat hypogonadal men with testosterone, we often see improvements in mood, energy, and motivation. But clinicians need to monitor for irritability and mood swings, particularly during the dose-titration phase" 5.

Bupropion is prescribed specifically to treat depression, and its efficacy for major depressive disorder is well-established across multiple randomized trials 11. The combination of testosterone replacement and antidepressant therapy in hypogonadal men with depression was examined in a randomized trial by Pope et al. (N=100), which found that testosterone augmentation of an antidepressant produced greater improvement in Hamilton Depression Rating Scale scores compared to antidepressant plus placebo in men with low testosterone and treatment-resistant depression 12.

Monitoring should include standardized depression screening (PHQ-9) at baseline and quarterly during the first year. Watch for bupropion-related activation (insomnia, agitation) that might be misattributed to testosterone, and testosterone-related irritability that might be misattributed to treatment failure of bupropion. The two effects can mimic each other.

Practical Prescribing Protocol for Co-Administration

Start with the drug that addresses the more urgent clinical need. If the patient's depression is the primary concern, stabilize on bupropion first (typically 150 mg daily for 3-7 days, then 300 mg daily). Once bupropion is stable for 2-4 weeks, initiate Jatenzo at 237 mg twice daily with food, which is the standard starting dose per the FDA label 3.

If hypogonadal symptoms are the primary concern, start Jatenzo and add bupropion after confirming that testosterone levels are within range (typically 300-1 to 000 ng/dL) at the 4-week follow-up.

The American Association of Clinical Endocrinologists (AACE) recommends that testosterone therapy monitoring include total testosterone, free testosterone, hematocrit, PSA, and lipid panel at 3 months and then every 6-12 months 13. When bupropion is co-prescribed, add blood pressure checks and a seizure risk assessment using the factors listed in bupropion's labeling: history of seizures, bulimia/anorexia nervosa, abrupt discontinuation of alcohol or sedatives, and concurrent use of other seizure-threshold-lowering agents.

When to Avoid the Combination

The combination should be avoided in three specific scenarios. First, patients with a history of seizure disorder, because bupropion alone is relatively contraindicated in this group 4. Second, patients with uncontrolled hypertension (systolic consistently above 160 mmHg), because additive BP effects could increase cardiovascular event risk. Third, patients with known polycythemia vera or baseline hematocrit above 50%, in whom testosterone initiation itself requires caution per Endocrine Society criteria 5.

For patients who cannot take bupropion due to seizure risk, alternative antidepressants with favorable sexual-side-effect profiles include mirtazapine and vilazodone, neither of which carries a significant seizure risk or CYP2D6 inhibition.

Summary of Drug-Interaction Databases

Major drug-interaction databases classify the Jatenzo-bupropion interaction as follows. Lexicomp rates it as a "C" interaction (monitor therapy). Clinical Pharmacology rates it as moderate. Micromedex lists no direct interaction between oral testosterone undecanoate and bupropion specifically, though it flags the CYP2D6 inhibition class effect. No database rates this combination as contraindicated or severe.

The FDA Adverse Event Reporting System (FAERS) contains no signal for the combination of oral testosterone undecanoate and bupropion as of available public data through 2025 14. This absence of signal, while not proof of safety, is consistent with the pharmacologic prediction that the interaction is modest.

Prescribers should document the interaction assessment, confirm the absence of seizure risk factors, and schedule blood pressure and hematocrit monitoring at 6-week and 3-month intervals after co-initiation.